Company: PTPI
Filing Date: 2025-02-10
Form Type: S-1/A
Source: 0001410578-25-000108
Chunk: 28

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-10
Form: S-1/A
Chunk 28
---
 no guarantee that it will ever be obtained. In the event that we cannot obtain the Warrant Stockholder Approval, the Series Warrants may never become exercisable. If we are unable to obtain the Warrant Stockholder Approval, the Series Warrants will have no value.

We have agreed to hold a special meeting of stockholders (which may also be at the annual meeting of shareholders) at the earliest practicable date after the date hereof, but in no event later than 60 days after the closing of the offering (the “Stockholder Meeting Deadline”), in order to obtain the Warrant Stockholder Approval. If, despite the Company’s reasonable best efforts the Warrant Stockholder Approval is not obtained on or prior to the Stockholder Meeting Deadline, the Company shall cause an additional stockholder meeting to be held on or prior to the ninetieth (90th) calendar day following the failure to obtain Warrant Stockholder Approval. If, despite the Company’s reasonable best efforts the Stockholder Approval is not obtained after such subsequent stockholder meetings, the Company shall cause an additional stockholder meeting to be held every ninety days thereafter until (i) such Warrant Stockholder Approval is obtained, or (ii) December 31, 2025, whichever is sooner. There is no guarantee we will be able to hold a special meeting within this timeframe, or at all.

<div align='center'>14</div>

The Series A Warrants contain anti-dilution provisions that may result in the reduction of the exercise price of the Series A Warrants in the future. This feature may result in an indeterminate number of shares of common stock being issued upon conversion or exercise, as applicable. The terms of the Series A Warrants contain anti-dilution provisions, which provisions require the lowering of the exercise price to the purchase price of future offerings. If in the future we issue securities for less than the exercise price of the Series A Warrants, we will be required to further reduce the relevant exercise price, which will result in a greater number of shares of common stock being issuable upon exercise of the Series A Warrants, which in turn will have a greater dilutive effect on our stockholders. As such, it is possible that we will not have sufficient available shares to satisfy the exercise of the Series A Warrants if we enter into a future transaction that lowers the exercise price. If we do not have sufficient available shares for the exercise of the Series A Warrants, we will be required to increase our authorized shares, which may